GHK-Cu vs AHK-Cu: what the science actually supports

What's this video probably claiming?

Based on the caption and hashtag context, this creator is drawing a clean line between two copper peptides: GHK-Cu handles skin repair, collagen synthesis, and skin tightening, while AHK-Cu is the hair-specific option for follicle strength and strand thickness. The framing is confident and prescriptive, which is common in the peptide content space. The hashtag peptidetherapy signals the creator likely positions these compounds as therapeutic interventions, not just cosmetic ingredients. At 107K views, this kind of tidy "peptide A does X, peptide B does Y" breakdown spreads fast because it feels actionable. The trouble is that real peptide biology is messier than that. Both compounds share copper-chelating activity. Both have shown activity in skin tissue. The clean division the caption implies probably overstates how distinct their mechanisms actually are, and there's next to no head-to-head human trial data to back up the split.

What does the science actually show?

GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is the more studied of the two. Pickart and Margolina (2018, Cosmetics) reviewed decades of data showing GHK-Cu stimulates collagen and glycosaminoglycan synthesis in fibroblast cultures, increases wound contraction rates, and modulates matrix metalloproteinases. A double-blind trial by Leyden et al. (2005) found a topical 3% GHK-Cu formulation improved skin laxity and reduced wrinkle depth after 12 weeks. For hair, Kessler et al. (2006, Archives of Dermatological Research) demonstrated GHK-Cu stimulated hair follicle size and elongation in vitro. AHK-Cu (alanyl-histidyl-lysine-copper) research is considerably thinner. Most citations circulating online trace back to in vitro work and a small number of industry-funded studies. There is genuine mechanistic rationale for follicle-specific activity, but strong, peer-reviewed, independent human trial data for AHK-Cu specifically is sparse enough that strong efficacy claims should be treated skeptically.

Where does the social media noise diverge from clinical reality?

The biggest divergence is certainty. Social media frames both peptides as delivering defined, predictable outcomes. Clinical reality is that topical peptide delivery is constrained by molecular weight, skin barrier function, and formulation chemistry. GHK-Cu has a molecular weight around 340 Da, which places it on the edge of effective transdermal penetration, and results in human trials are real but modest, not transformative. The Leyden (2005) wrinkle data showed improvements in the range of 10-15%, which is meaningful but not the "tighter, brighter" revolution the caption implies. For hair, the follicle research on GHK-Cu, let alone AHK-Cu, is almost entirely preclinical or industry-sponsored. Conflating in vitro follicle stimulation with "thicker strands" in real humans is a significant leap. The hashtag peptidetherapy also blurs an important line: topical cosmetic use and injectable peptide therapy are categorically different regulatory and clinical contexts, and content that blends them misleads audiences about what each actually involves.

What should you actually know?

GHK-Cu has a legitimate, if imperfect, evidence base for topical skin applications. The collagen and wound-healing data is real, the mechanism is plausible, and some human trials support modest cosmetic benefit. If you're looking at GHK-Cu in a skincare product, that's a reasonable ingredient to evaluate. AHK-Cu is a different story. The follicle-specific claims are largely built on mechanistic logic and limited independent data. That doesn't make it useless, but it does mean anyone selling certainty about AHK-Cu outcomes is running ahead of the evidence. The idea that these two peptides have clean, non-overlapping jobs is a simplification that makes for good content but poor biology. If you're considering either peptide in any injectable or systemic context, that conversation belongs with a licensed clinician who can assess your individual situation. Cosmetic ingredient and therapeutic compound are not interchangeable categories, regardless of what a TikTok caption implies.